PL207022B1 - Zastosowanie Inhibitora kinazy-3 syntazy glikogenowej (GSK-3) - Google Patents
Zastosowanie Inhibitora kinazy-3 syntazy glikogenowej (GSK-3)Info
- Publication number
- PL207022B1 PL207022B1 PL369130A PL36913002A PL207022B1 PL 207022 B1 PL207022 B1 PL 207022B1 PL 369130 A PL369130 A PL 369130A PL 36913002 A PL36913002 A PL 36913002A PL 207022 B1 PL207022 B1 PL 207022B1
- Authority
- PL
- Poland
- Prior art keywords
- amino
- phenylaminothiazol
- methanone
- thiazol
- ylmethanone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32539001P | 2001-09-27 | 2001-09-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL369130A1 PL369130A1 (en) | 2005-04-18 |
| PL207022B1 true PL207022B1 (pl) | 2010-10-29 |
Family
ID=23267686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL369130A PL207022B1 (pl) | 2001-09-27 | 2002-09-23 | Zastosowanie Inhibitora kinazy-3 syntazy glikogenowej (GSK-3) |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7598288B2 (https=) |
| EP (2) | EP2281560A1 (https=) |
| JP (2) | JP2005504101A (https=) |
| KR (1) | KR20040047824A (https=) |
| CN (2) | CN1561393A (https=) |
| AR (1) | AR036684A1 (https=) |
| AU (1) | AU2002334635B2 (https=) |
| BR (1) | BR0212924A (https=) |
| CA (1) | CA2460000C (https=) |
| MX (1) | MXPA04002137A (https=) |
| PL (1) | PL207022B1 (https=) |
| RU (1) | RU2297243C2 (https=) |
| TW (2) | TW201041580A (https=) |
| WO (1) | WO2003027275A1 (https=) |
| ZA (1) | ZA200401846B (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7101666B2 (en) * | 2001-08-31 | 2006-09-05 | Centre For Addiction And Mental Health | Involvement of the BDNF gene in mood disorders |
| WO2003092584A2 (en) | 2002-04-30 | 2003-11-13 | Alcon, Inc. | Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
| EP1925306A3 (en) * | 2002-04-30 | 2008-09-17 | Alcon, Inc. | Agents which Regulate, Inhibit, or Modulate the Activity and/or Expression of Connective Tissue Growth Factor (CTGF) to Lower Intraocular Pressure |
| WO2004103958A2 (en) | 2003-05-19 | 2004-12-02 | Michigan State University | Preparation of hymenialdisine derivatives and use thereof |
| TW200526224A (en) * | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| EP1696926A1 (en) * | 2003-12-22 | 2006-09-06 | Alcon, Inc. | Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration |
| PL1696958T3 (pl) * | 2003-12-22 | 2007-08-31 | Alcon Inc | Środki do leczenia retinopatii jaskrowej i neuropatii wzrokowej |
| US20070167329A1 (en) * | 2003-12-24 | 2007-07-19 | Bayer Cropscience Gmbh | Plant growth regulation |
| US20080096238A1 (en) * | 2004-03-30 | 2008-04-24 | Alcon, Inc. | High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio |
| WO2005102345A1 (en) * | 2004-03-30 | 2005-11-03 | Alcon, Inc. | Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance |
| EP1746886A1 (en) * | 2004-05-12 | 2007-01-31 | Bayer CropScience GmbH | Plant growth regulation |
| WO2006089874A1 (en) * | 2005-02-22 | 2006-08-31 | Gpc Biotech Ag | Benzo[2,3]azepino[4,5-b]indol-6-ones |
| KR20080018858A (ko) | 2005-03-11 | 2008-02-28 | 알콘, 인코퍼레이티드 | 녹내장 치료용 플리즐 관련 단백질―１의 ＲＮＡⅰ－중재저해 |
| RU2284192C1 (ru) * | 2005-04-01 | 2006-09-27 | Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова Министерства здравоохранения РФ | Способ лечения глаукомной оптической нейропатии |
| US20080207594A1 (en) | 2005-05-04 | 2008-08-28 | Davelogen Aktiengesellschaft | Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders |
| EP1757607A1 (en) | 2005-08-24 | 2007-02-28 | Molisa GmbH | N5-substituted benzo¬2,3|azepino¬4,5-b|indol-6-ones for treating tropical diseases |
| WO2007030680A2 (en) * | 2005-09-07 | 2007-03-15 | Rigel Pharmaceuticals, Inc. | Triazole derivatives useful as axl inhibitors |
| CA2653903A1 (en) * | 2006-06-12 | 2007-12-21 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| ES2672172T3 (es) | 2006-12-29 | 2018-06-12 | Rigel Pharmaceuticals, Inc. | Triazoles N3-heteroarilsustituidos y triazoles N5-heteroarilsustituidos útiles como inhibidores de Axl |
| EP2078010B1 (en) | 2006-12-29 | 2014-01-29 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| EP2114955B1 (en) | 2006-12-29 | 2013-02-13 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| EP2079736B1 (en) | 2006-12-29 | 2017-10-18 | Rigel Pharmaceuticals, Inc. | Substituted triazoles useful as axl inhibitors |
| WO2008083353A1 (en) | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| WO2009054864A1 (en) | 2007-10-26 | 2009-04-30 | Rigel Pharmaceuticals, Inc. | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| US8431594B2 (en) | 2008-07-09 | 2013-04-30 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors |
| CA2730231C (en) | 2008-07-09 | 2016-10-18 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| SG172997A1 (en) | 2009-01-16 | 2011-08-29 | Rigel Pharmaceuticals Inc | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
| UA103918C2 (en) * | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| RU2456266C1 (ru) * | 2011-04-06 | 2012-07-20 | Максим Эдуардович Запольский | Производные 4,4'-бифениламидов, обладающие фармакологической активностью, и лекарственные средства на их основе |
| US20160040247A1 (en) | 2013-03-15 | 2016-02-11 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Method for the diagnosis, prognosis, and tratment of cancer metastasis |
| US10143703B2 (en) | 2014-01-02 | 2018-12-04 | Massachusetts Eye And Ear Infirmary | Treating ocular neovascularization |
| US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| US11045352B2 (en) | 2014-05-12 | 2021-06-29 | Gholam A. Peyman | Methods for treatment of dry eye and other acute or chronic inflammatory processes |
| US10583221B2 (en) | 2014-05-12 | 2020-03-10 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
| US10881503B2 (en) | 2014-05-12 | 2021-01-05 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
| US11666777B2 (en) | 2014-05-12 | 2023-06-06 | Gholam A. Peyman | Photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient |
| US10925889B2 (en) | 2014-05-12 | 2021-02-23 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| US11338059B2 (en) | 2014-05-12 | 2022-05-24 | Gholam A. Peyman | Method of corneal and scleral inlay crosslinking and preservation |
| US11565023B2 (en) | 2014-05-12 | 2023-01-31 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
| US11648261B2 (en) | 2014-05-12 | 2023-05-16 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| US12396889B2 (en) | 2014-05-12 | 2025-08-26 | Gholam A. Peyman | Lamellar corneal autologous or homologous graft in refractive surgery |
| TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| WO2019221959A1 (en) * | 2018-05-16 | 2019-11-21 | Peyman Gholam A | Method of treating, reducing, or alleviating a medical condition in a patient |
| US11707518B2 (en) | 2019-04-28 | 2023-07-25 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| US12226478B2 (en) | 2019-04-28 | 2025-02-18 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| US12110278B2 (en) * | 2020-10-13 | 2024-10-08 | Yale University | Selective JAK2 pseudokinase ligands and methods of use |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ280738B6 (cs) | 1988-02-10 | 1996-04-17 | F. Hoffmann - La Roche And Co., Aktiengesellschaft | Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi |
| MC2096A1 (fr) | 1989-02-23 | 1991-02-15 | Hoffmann La Roche | Pyrroles substitues |
| CA2015996C (en) | 1989-05-05 | 2001-08-28 | Hartmut Osswald | Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals |
| DE3914764A1 (de) | 1989-05-05 | 1990-11-08 | Goedecke Ag | Maleinimid-derivate und deren verwendung als arzneimittel |
| DE4005970A1 (de) | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
| DE4005969A1 (de) | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
| CA2046801C (en) | 1990-08-07 | 2002-02-26 | Peter D. Davis | Substituted pyrroles |
| HUT70187A (en) | 1991-04-11 | 1995-09-28 | Schering Corp | Process for preparing oxadiazepine derivatives condensed with indole and pharmaceutical compositions of anti-tumor and anti-psoriatic activity containing said compounds |
| GB9123396D0 (en) | 1991-11-04 | 1991-12-18 | Hoffmann La Roche | A process for the manufacture of substituted maleimides |
| WO1993018765A1 (en) | 1992-03-20 | 1993-09-30 | The Wellcome Foundation Limited | Indole derivatives with antiviral activity |
| US5547976A (en) | 1992-03-20 | 1996-08-20 | Burroughs Wellcome Co. | Further indole derivatives with antiviral activity |
| DE4217964A1 (de) | 1992-05-30 | 1993-12-02 | Goedecke Ag | Indolocarbazol-Imide und deren Verwendung |
| DE4243321A1 (de) | 1992-12-21 | 1994-06-23 | Goedecke Ag | Aminosäurederivate von Heterocyclen als PKC-Inhibitoren |
| GB9319297D0 (en) | 1993-09-17 | 1993-11-03 | Wellcome Found | Indole derivatives |
| GB9416467D0 (en) | 1994-08-13 | 1994-10-05 | Wellcome Found | Compounds for use in medicine |
| US5681854A (en) * | 1995-11-22 | 1997-10-28 | Alcon Laboratories, Inc. | Use of aliphatic carboxylic acid derivatives in ophthalmic disorders |
| US6057117A (en) | 1996-04-04 | 2000-05-02 | Chiron Corporation | Identification and use of selective inhibitors of glycogen synthase kinase 3 |
| EP1019043A4 (en) * | 1996-05-07 | 2003-07-30 | Univ Pennsylvania | INHIBITORS OF GLYCOGEN SYNTHESIS KINASE 3 AND METHOD FOR THEIR IDENTIFICATION AND USE |
| PE91598A1 (es) | 1996-07-29 | 1998-12-24 | Hoffmann La Roche | Pirroles sustituidos |
| PE91698A1 (es) * | 1996-07-29 | 1998-12-24 | Hoffmann La Roche | Pirroles sustituidos |
| PE91498A1 (es) | 1996-07-29 | 1998-12-22 | Hoffmann La Roche | Pirroles sustituidos |
| SE9603283D0 (sv) | 1996-09-10 | 1996-09-10 | Astra Ab | New compounds |
| SE9603285D0 (sv) | 1996-09-10 | 1996-09-10 | Astra Ab | New compounds |
| CA2297967A1 (en) * | 1997-08-07 | 1999-02-18 | The Regents Of The University Of California | Purine inhibitor of protein kinases, g proteins and polymerases |
| AU2548699A (en) | 1998-02-23 | 1999-09-06 | Rei Asakai | Cell death inhibitors |
| JP2002516851A (ja) | 1998-05-29 | 2002-06-11 | ゲルハルト アイゼンブランド | サイクリン依存性キナーゼを阻害する医薬製造のためのインジゴイドビスインドール誘導体の使用 |
| ATE284387T1 (de) | 1998-10-08 | 2004-12-15 | Smithkline Beecham Plc | 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) |
| GB9828640D0 (en) | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
| GB9918180D0 (en) | 1999-08-02 | 1999-10-06 | Smithkline Beecham Plc | Novel compositions |
| AU6593600A (en) * | 1999-08-20 | 2001-03-19 | Rei Asakai | Drugs inhibiting cell death |
| FR2801216A1 (fr) | 1999-11-23 | 2001-05-25 | Centre Nat Rech Scient | Utilisation de derives d'indirubine pour la fabrication de medicaments |
| EP1106180B1 (en) | 1999-12-08 | 2003-11-12 | Centre National de la Recherche Scientifique (CNRS) | Use of hymenialdisine or derivatives thereof in the manufacture of medicaments |
| EP1244461A2 (en) | 1999-12-23 | 2002-10-02 | The Ontario Cancer Institute | INHIBITION OF GSK-3$g(b) |
| WO2001049709A1 (en) | 2000-01-03 | 2001-07-12 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Glycogen synthase kinase-3 inhibitors |
| WO2001056567A1 (en) | 2000-02-04 | 2001-08-09 | Novo Nordisk A/S | 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors |
| EP1974738A3 (en) | 2000-02-29 | 2008-12-17 | Alcon, Inc. | Diagnostics and therapeutics for glaucoma |
| EP1136099A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Indolylalkylamino)pyrimidone derivatives as GSK3beta inhibitors |
| AU2001248365A1 (en) * | 2000-03-23 | 2001-10-03 | Mitsubishi Pharma Corporation | 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives |
| EP1136482A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
| AU2002350487C1 (en) | 2001-09-21 | 2008-10-02 | Mitsubishi Pharma Corporation | Substituted 2-pyridinyl-6,7,8,9- tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives |
-
2002
- 2002-09-10 TW TW099127943A patent/TW201041580A/zh unknown
- 2002-09-10 TW TW091120600A patent/TWI335221B/zh not_active IP Right Cessation
- 2002-09-23 US US10/488,496 patent/US7598288B2/en not_active Expired - Fee Related
- 2002-09-23 AU AU2002334635A patent/AU2002334635B2/en not_active Ceased
- 2002-09-23 WO PCT/US2002/030059 patent/WO2003027275A1/en not_active Ceased
- 2002-09-23 BR BR0212924-8A patent/BR0212924A/pt not_active IP Right Cessation
- 2002-09-23 MX MXPA04002137A patent/MXPA04002137A/es active IP Right Grant
- 2002-09-23 JP JP2003530847A patent/JP2005504101A/ja active Pending
- 2002-09-23 CA CA2460000A patent/CA2460000C/en not_active Expired - Fee Related
- 2002-09-23 CN CNA028190106A patent/CN1561393A/zh active Pending
- 2002-09-23 RU RU2004112766/14A patent/RU2297243C2/ru not_active IP Right Cessation
- 2002-09-23 CN CNA2008100990379A patent/CN101380319A/zh active Pending
- 2002-09-23 EP EP10181455A patent/EP2281560A1/en not_active Withdrawn
- 2002-09-23 KR KR10-2004-7003638A patent/KR20040047824A/ko not_active Ceased
- 2002-09-23 PL PL369130A patent/PL207022B1/pl not_active IP Right Cessation
- 2002-09-23 EP EP02799603A patent/EP1430120A4/en not_active Withdrawn
- 2002-09-26 AR ARP020103638A patent/AR036684A1/es unknown
-
2004
- 2004-03-05 ZA ZA200401846A patent/ZA200401846B/en unknown
-
2005
- 2005-07-21 JP JP2005211956A patent/JP2005320350A/ja active Pending
-
2009
- 2009-08-21 US US12/545,611 patent/US20090312390A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7598288B2 (en) | 2009-10-06 |
| TWI335221B (en) | 2011-01-01 |
| RU2004112766A (ru) | 2005-03-27 |
| CA2460000A1 (en) | 2003-04-03 |
| EP2281560A1 (en) | 2011-02-09 |
| PL369130A1 (en) | 2005-04-18 |
| US20040186159A1 (en) | 2004-09-23 |
| RU2297243C2 (ru) | 2007-04-20 |
| JP2005504101A (ja) | 2005-02-10 |
| EP1430120A4 (en) | 2007-06-20 |
| AU2002334635B2 (en) | 2007-06-21 |
| WO2003027275A1 (en) | 2003-04-03 |
| AR036684A1 (es) | 2004-09-29 |
| MXPA04002137A (es) | 2004-06-29 |
| ZA200401846B (en) | 2005-03-07 |
| EP1430120A1 (en) | 2004-06-23 |
| TW201041580A (en) | 2010-12-01 |
| KR20040047824A (ko) | 2004-06-05 |
| CN101380319A (zh) | 2009-03-11 |
| CA2460000C (en) | 2013-01-29 |
| US20090312390A1 (en) | 2009-12-17 |
| BR0212924A (pt) | 2005-01-04 |
| JP2005320350A (ja) | 2005-11-17 |
| CN1561393A (zh) | 2005-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL207022B1 (pl) | Zastosowanie Inhibitora kinazy-3 syntazy glikogenowej (GSK-3) | |
| AU2002334635A1 (en) | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma | |
| JP4934653B2 (ja) | Ｒｈｏキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤 | |
| KR101092048B1 (ko) | Ｒｈｏ 키나아제 억제제 및 프로스타글란딘류를 포함하는녹내장 치료제 | |
| US6271224B1 (en) | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia | |
| US20120115870A1 (en) | Control of intraocular pressure using alk5 modulation agents | |
| EP2319539A1 (en) | Prophylactic or therapeutic agent for axial myopia | |
| Maślanka | A review of the pharmacology of carbonic anhydrase inhibitors for the treatment of glaucoma in dogs and cats | |
| WO2006062731A1 (en) | Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye | |
| KR20210010638A (ko) | 다이피리다몰을 이용하여 눈 장애를 치료하는데 사용하기 위한 조성물 | |
| CZ285129B6 (cs) | Oftalmické přípravky, obsahující kombinace inhibitoru karboanhydrasy a beta-adrenergního antagonisty | |
| WO2019131901A1 (ja) | ピリジルアミノ酢酸化合物を含有する医薬製剤 | |
| US20120316143A1 (en) | Ophthalmic composition | |
| EP1859795A1 (en) | Therapeutic agent for ophthalmic disease | |
| JP2001504100A (ja) | 緑内障を治療するための炭酸脱水素酵素阻害剤とプロスタグランジンとの組合せの使用 | |
| HK1153935A (en) | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucomatous optic neuropathy | |
| KR20080111092A (ko) | 고안압증 조절 및 녹내장의 치료를 위한 프레닐트랜스퍼라아제 억제제 | |
| US20060211700A1 (en) | (R)-8,9-dichloro-2,3,4,4a-tetrahydro-1H,6H-pyrazino[1,2-a]quinoxalin-5-one for controlling IOP and treating glaucoma | |
| KR20240019817A (ko) | 퇴행성 망막 질환에 사용하기 위한 trpa1 채널 길항제 화합물 | |
| CA2434691A1 (en) | Use of propentofylline to control intraocular pressure | |
| US20040110776A1 (en) | Use of propentofylline to control intraocular pressure | |
| HK40031074A (en) | Pharmaceutical preparation containing pyridyl aminoacetic acid compound | |
| MX2008007845A (en) | Control of intraocular pressure using alk5 modulation agents | |
| EP0375319A3 (en) | Angiotensin converting enzyme inhibitors in the treatment of glaucoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20130923 |